Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, April 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 204 articles:
HTML format


 

Single Articles

  1. YU G, Zhou H, Yao W, Meng L, et al
    lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer.
    Mol Ther Nucleic Acids. 2019;16:257-271.
    Abstract    

    Abstract available

  2. HASSANIEN OA, Abouelkheir RT, Abou El-Ghar MI, Badawy ME, et al
    Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Diagnostic Tool in the Assessment of Tumour Angiogenesis in Urinary Bladder Cancer.
    Can Assoc Radiol J. 2019 Mar 25. pii: S0846-5371(18)30206.
    Abstract    

    Abstract available

  3. AMIN RW, Stafford B, Guttmann RP
    A spatial study of bladder cancer mortality and incidence in the contiguous US: 2000-2014.
    Sci Total Environ. 2019;670:806-813.
    Abstract    

    Abstract available

  4. HERNANDEZ P, Alem D, Nieves M, Cerecetto H, et al
    Chemosensitizer effect of cisplatin-treated bladder cancer cells by phenazine-5,10-dioxides.
    Environ Toxicol Pharmacol. 2019;69:9-15.
    Abstract    

    Abstract available

  5. WISSING MD, Santos F, Zakaria AS, O'Flaherty A, et al
    Short- and long-term survival has improved after radical cystectomy for bladder cancer in Quebec during the years 2000-2015.
    J Surg Oncol. 2019 Mar 28. doi: 10.1002/jso.25456.
    Abstract    

    Abstract available

  6. ZHANG L, Wu B, Zha Z, Zhao H, et al
    Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis.
    World J Urol. 2019 Mar 27. pii: 10.1007/s00345-019-02738.
    Abstract    

    Abstract available

  7. LUO H, Xu C, Le W, Ge B, et al
    lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150.
    J Cell Biochem. 2019 Mar 27. doi: 10.1002/jcb.28622.
    Abstract    

    Abstract available

  8. ZHANG L, Yan R, Zhang SN, Zhang HZ, et al
    MicroRNA-338-3p inhibits the progression of bladder cancer through regulating ETS1 expression.
    Eur Rev Med Pharmacol Sci. 2019;23:1986-1995.
    Abstract    

    Abstract available

  9. BRIEU N, Gavriel CG, Nearchou IP, Harrison DJ, et al
    Automated tumour budding quantification by machine learning augments TNM staging in muscle-invasive bladder cancer prognosis.
    Sci Rep. 2019;9:5174.
    Abstract    

    Abstract available

  10. LI A, Zhu X, Wang C, Yang S, et al
    Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer.
    Sci Rep. 2019;9:5166.
    Abstract    

    Abstract available

  11. CHENG S, Qian K, Wang Y, Wang G, et al
    PPARgamma inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells.
    J Cell Mol Med. 2019 Mar 25. doi: 10.1111/jcmm.14280.
    Abstract    

    Abstract available

  12. ZHANG G, Steinbach D, Grimm MO, Horstmann M, et al
    Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    World J Urol. 2019 Mar 25. pii: 10.1007/s00345-019-02681.
    Abstract    

    Abstract available

  13. YOSHIKAWA Y, Taniguchi K, Tsujino T, Heishima K, et al
    Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment.
    Mol Ther Methods Clin Dev. 2019;13:290-302.
    Abstract    

    Abstract available

  14. SUBIRA-RIOS D, Herranz-Amo F, Renedo-Villar T, Moralejo-Garate M, et al
    Influence of laparoscopic access in cancer-specific mortality of patients with pTa-2pN0R0 bladder cancer treated with radical cistectomy.
    Actas Urol Esp. 2019 Mar 22. pii: S0210-4806(19)30004.
    Abstract    

    Abstract available

  15. CAO W, Zhao Y, Wang L, Huang X, et al
    Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression.
    Cancer Biomark. 2019 Mar 12. pii: CBM182380. doi: 10.3233/CBM-182380.
    Abstract    

    Abstract available

  16. SU H, Jiang H, Tao T, Kang X, et al
    Hope and challenge: Precision medicine in bladder cancer.
    Cancer Med. 2019 Mar 24. doi: 10.1002/cam4.1979.
    Abstract    

    Abstract available

  17. ROSSI M, Strikoudi P, Spei ME, Parpinel M, et al
    Flavonoids and bladder cancer risk.
    Cancer Causes Control. 2019 Mar 22. pii: 10.1007/s10552-019-01158.
    Abstract    

    Abstract available

  18. GUO X, Liu M, Hou H, Liu S, et al
    Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
    Int J Clin Oncol. 2019 Mar 22. pii: 10.1007/s10147-019-01427.
    Abstract    

    Abstract available

  19. VAN OSCH FHM, Nekeman D, Aaronson NK, Billingham LJ, et al
    Patients choose certainty over burden in bladder cancer surveillance.
    World J Urol. 2019 Mar 23. pii: 10.1007/s00345-019-02728.
    Abstract    

    Abstract available

  20. ZHOU Q, Zhan H, Lin F, Liu Y, et al
    LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase (GLS) expression.
    Biosci Rep. 2019 Mar 22. pii: BSR20182372. doi: 10.1042/BSR20182372.
    Abstract    

    Abstract available

  21. OGAWA K, Shimizu Y, Tsuchihashi K, Kida K, et al
    [Two Cases of Inflammatory Myofibroblastic Tumor of the Urinary Bladder].
    Hinyokika Kiyo. 2018;64:445-450.
    Abstract    

    Abstract available

  22. CAO Q, Li P, Yang X, Qian J, et al
    Laparoscopic radical cystectomy with pelvic re-peritonealization: the technique and initial clinical outcomes.
    BMC Urol. 2018;18:113.
    Abstract    

    Abstract available

  23. OSMANOV YI, Gaibov ZA, Kogan EA, Radenska-Lopovok SG, et al
    [Comparative morphological characteristics and immunophenotype of urothelial carcinomas of the renal pelvis and bladder].
    Arkh Patol. 2018;80:23-32.
    Abstract    

    Abstract available

  24. MURAKAMI M, Kimura T, Iwamoto M, Honda M, et al
    [A Case of Metachronous Cancer Originating from Five Different Organs].
    Hinyokika Kiyo. 2018;64:231-234.
    Abstract    

    Abstract available

  25. KURAMOTO T, Nishikawa T, Nanpou Y
    [A Case Report of Granulomatous Renal Masses Following Intravesical Instillation of Bacillus Calmette-Guerin Therapy].
    Hinyokika Kiyo. 2018;64:225-230.
    Abstract    

    Abstract available

  26. SHI H, Yu H, Bellmunt J, Leow JJ, et al
    Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis.
    Qual Life Res. 2018;27:2759-2775.
    Abstract    

    Abstract available

  27. OKUMURA A, Morii A, Takagawa K, Kitamura H, et al
    [A Case of Metastasis of Cholangiocarcinoma to the Bladder].
    Hinyokika Kiyo. 2018;64:165-168.
    Abstract    

    Abstract available

  28. SHIMURA S, Matsumoto K, Tabata KI, Fujita T, et al
    [Recurrent Urothelial Carcinoma in the Uretero-Vesical Junction Treated with Partial Ureterectomy and Ureteroneocystostomy during Long-Term Follow-Up : A Case Report].
    Hinyokika Kiyo. 2018;64:157-160.
    Abstract    

    Abstract available

  29. MU XY, Wang RJ, Yao ZX, Zheng Z, et al
    RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment.
    Mol Immunol. 2019;109:140-148.
    Abstract    

    Abstract available

  30. PRAKASH G, Pal M, Odaiyappan K, Shinde R, et al
    Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India.
    Indian J Cancer. 2019;56:54-58.
    Abstract    

    Abstract available

  31. ZHU Q, Sheng Y, Li W, Wang J, et al
    Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits bladder cancer cell growth via the mitochondrial apoptosis and JNK pathways.
    Toxicol Appl Pharmacol. 2019 Apr 1. pii: S0041-008X(19)30117.
    Abstract    

    Abstract available

  32. YU CC, Li CF, Chen IH, Lai MT, et al
    YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo-/radio-resistance by suppressing caspase-mediated apoptosis.
    J Pathol. 2019 Apr 3. doi: 10.1002/path.5274.
    Abstract    

    Abstract available

  33. BOERI L, Montanari E, Karnes RJ
    Reply letter to: Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol. 2018 Nov 1;4(11):1535-1542.
    World J Urol. 2019 Apr 3. pii: 10.1007/s00345-019-02751.
    Abstract    



  34. NICOLAZZO C, Busetto GM, Gradilone A, Sperduti I, et al
    Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial.
    Oncologist. 2019 Apr 3. pii: theoncologist.2018-0784.
    Abstract    

    Abstract available

  35. FLANNERY K, Boyd M, Black-Shinn J, Robert N, et al
    Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.
    Future Oncol. 2019 Apr 3. doi: 10.2217/fon-2018-0654.
    Abstract    

    Abstract available

  36. KACHRILAS S, Dellis A, Papatsoris A, Avgeris S, et al
    PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer.
    J BUON. 2019;24:329-337.
    Abstract    

    Abstract available

  37. LIANG T, Wang Y, Wang Y, Wang Y, et al
    Long noncoding RNA PEG10 facilitates bladder cancer cells proliferation, migration, and invasion via repressing microRNA-29b.
    J Cell Physiol. 2019 Apr 2. doi: 10.1002/jcp.28574.
    Abstract    

    Abstract available

  38. OH JJ, Byun SS, Jeong CW, Kwak C, et al
    Association Between Preoperative Hydronephrosis and Prognosis After Radical Cystectomy Among Patients With Bladder Cancer: A Systemic Review and Meta-Analysis.
    Front Oncol. 2019;9:158.
    Abstract    

    Abstract available

  39. BODGI L, Bahmad HF, Araji T, Al Choboq J, et al
    Assessing Radiosensitivity of Bladder Cancer in vitro: A 2D vs. 3D Approach.
    Front Oncol. 2019;9:153.
    Abstract    

    Abstract available

  40. MIAO L, Liu HY, Zhou C, He X, et al
    LINC00612 enhances the proliferation and invasion ability of bladder cancer cells as ceRNA by sponging miR-590 to elevate expression of PHF14.
    J Exp Clin Cancer Res. 2019;38:143.
    Abstract    

    Abstract available

  41. HAGGSTROM C, Garmo H, de Luna X, Van Hemelrijck M, et al
    Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: A Swedish nationwide population-based cohort study.
    Cancer Med. 2019 Apr 1. doi: 10.1002/cam4.2126.
    Abstract    

    Abstract available

  42. XIE Q, Chen C, Li H, Xu J, et al
    miR-3687 Overexpression Promotes Bladder Cancer Cell Growth by Inhibiting the Negative Effect of FOXP1 on Cyclin E2 Transcription.
    Mol Ther. 2019 Mar 15. pii: S1525-0016(19)30092.
    Abstract    

    Abstract available

  43. SUBIRA-RIOS D, Herranz-Amo F, Moralejo-Garate M, Cano-Velasco J, et al
    Post-surgical complications in patients with bladder cancer treated with cystectomy: Differences between open and laparoscopic approach.
    Actas Urol Esp. 2019 Mar 29. pii: S0210-4806(19)30006.
    Abstract    

    Abstract available

  44. GAO H, Yu G, Zhang X, Yu S, et al
    BZW2 gene knockdown induces cell growth inhibition, G1 arrest and apoptosis in muscle-invasive bladder cancers: A microarray pathway analysis.
    J Cell Mol Med. 2019 Apr 1. doi: 10.1111/jcmm.14266.
    Abstract    

    Abstract available

  45. BEULENS AJW, van der Toorn PP, de Wildt MJ, Scheepens WA, et al
    High-precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-day Integrated Boost Technique with Image Guidance Using Lipiodol Markers.
    Eur Urol Oncol. 2019;2:39-46.
    Abstract    

    Abstract available

  46. ZEKRI AN, Khaled HM, Mohammed MB, Diab FM, et al
    Microsatellite instability profiling in Egyptian bladder cancer patients: A pilot study.
    Curr Probl Cancer. 2019 Mar 26. pii: S0147-0272(18)30459.
    Abstract    

    Abstract available

  47. YAN X, Guo ZX, Liu XP, Feng YJ, et al
    Four novel biomarkers for bladder cancer identified by weighted gene coexpression network analysis.
    J Cell Physiol. 2019 Mar 29. doi: 10.1002/jcp.28546.
    Abstract    

    Abstract available

  48. MAIA MC, Hansen A, Alves C, Salah S, et al
    Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review.
    Crit Rev Oncol Hematol. 2019;135:76-84.
    Abstract    

    Abstract available

  49. IZUMI K, Iwamoto H, Yaegashi H, Shigehara K, et al
    Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function.
    In Vivo. 2019;33:167-172.
    Abstract    

    Abstract available

  50. GARG G, Sharma A, Sharma A, Sankhwar S, et al
    Metastatic adenocarcinoma of bladder presenting with skin and visceral metastasis.
    BMJ Case Rep. 2018;11.
    Abstract    

    Abstract available

  51. PARK S, Reuter VE, Hansel DE
    Non-urothelial carcinomas of the bladder.
    Histopathology. 2019;74:97-111.
    Abstract    

    Abstract available

  52. MCKENNEY JK
    Precursor lesions of the urinary bladder.
    Histopathology. 2019;74:68-76.
    Abstract    

    Abstract available

  53. JAYARAJAH U, Fernando MH, Herath KB, Kuruppu SN, et al
    Clinico-pathological characteristics and outcome of upper urinary tract urothelial carcinoma presenting to a tertiary care urology unit in Sri Lanka
    Ceylon Med J. 2018;63:129-132.
    Abstract    

    Abstract available

  54. NILBERT M, Blackberg M, Ceberg J, Hagberg O, et al
    Diagnostic pathway efficacy for urinary tract cancer: population-based outcome of standardized evaluation for macroscopic haematuria.
    Scand J Urol. 2018;52:237-243.
    Abstract    

    Abstract available

  55. MINATO A, Noguchi H, Tomisaki I, Fukuda A, et al
    Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
    Cancer Control. 2018;25:1073274818800269.
    Abstract    

    Abstract available

  56. KARAOSMANOGLU AD, Onur MR, Karcaaltincaba M, Akata D, et al
    Secondary Tumors of the Urinary System: An Imaging Conundrum.
    Korean J Radiol. 2018;19:742-751.
    Abstract    

    Abstract available

  57. MORGANSTERN BA, Scaccia S, Wu W, Williamson AK, et al
    Synchronous, but separate, bladder and vaginal rhabdomyosarcoma: a novel genetic case report.
    Can J Urol. 2018;25:9357-9359.
    Abstract    

    Abstract available

  58. LEE AJ, Yabes JG, Hale N, Hrebinko RL, et al
    The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients.
    Can J Urol. 2018;25:9255-9261.
    Abstract    

    Abstract available

  59. HAO YC, Xiao CL, Liu K, Liu YQ, et al
    [Application of narrow-band imaging flexible ureteroscopy in the diagnosis, treatment and follow-up of upper tract urothelial carcinomas].
    Zhonghua Wai Ke Za Zhi. 2018;56:222-226.
    Abstract    

    Abstract available

  60. MCARDLE BJ, Vidal P, Psutka SP, Hollowell CMP, et al
    T4 urothelial carcinoma in undiagnosed closed bladder exstrophy in a post-menopausal female.
    Can J Urol. 2018;25:9214-9216.
    Abstract    

    Abstract available

  61. PIERCONTI F, Rossi ED, Straccia P, Fadda G, et al
    The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration.
    Cancer Cytopathol. 2018;126:200-206.
    Abstract    

    Abstract available

  62. WANG F, Zhang H, Ma AH, Yu W, et al
    COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.
    Mol Cancer Ther. 2018;17:474-483.
    Abstract    

    Abstract available

  63. WANG Y, Auger M, Kanber Y, Caglar D, et al
    Implementing The Paris System for Reporting Urinary Cytology results in a decrease in the rate of the "atypical" category and an increase in its prediction of subsequent high-grade urothelial carcinoma.
    Cancer Cytopathol. 2018;126:207-214.
    Abstract    

    Abstract available

  64. TRETIAKOVA M, Fulton R, Kocherginsky M, Long T, et al
    Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
    Mod Pathol. 2018;31:623-632.
    Abstract    

    Abstract available

  65. HINDY JR, Souaid T, Kourie HR, Kattan J, et al
    Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
    Future Oncol. 2019 Apr 12. doi: 10.2217/fon-2018-0459.
    Abstract    

    Abstract available

  66. YE X, Guo J, Zhang H, Meng Q, et al
    The enhanced expression of estrogen-related receptor alpha in human bladder cancer tissues and the effects of estrogen-related receptor alpha knockdown on bladder cancer cells.
    J Cell Biochem. 2019 Apr 11. doi: 10.1002/jcb.28657.
    Abstract    

    Abstract available

  67. PANG KH, Noon AP
    Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8:101-107.
    Abstract    

    Abstract available

  68. HENDRICKSEN K
    Device-assisted intravesical therapy for non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8:94-100.
    Abstract    

    Abstract available

  69. D'ANDREA D, Gontero P, Shariat SF, Soria F, et al
    Intravesical bacillus Calmette-Guerin for bladder cancer: are all the strains equal?
    Transl Androl Urol. 2019;8:85-93.
    Abstract    

    Abstract available

  70. ZAMBONI S, Baumeister P, Mattei A, Mordasini L, et al
    Single postoperative instillation for non-muscle invasive bladder cancer: are there still any indication?
    Transl Androl Urol. 2019;8:76-84.
    Abstract    

    Abstract available

  71. RINK M, Schwarzenbach H, Vetterlein MW, Riethdorf S, et al
    The current role of circulating biomarkers in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8:61-75.
    Abstract    

    Abstract available

  72. MARCQ G, Henon F, Ouzaid I, Fantoni JC, et al
    Active surveillance for non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8:54-60.
    Abstract    

    Abstract available

  73. SORIA F, Marra G, D'Andrea D, Gontero P, et al
    The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer.
    Transl Androl Urol. 2019;8:46-53.
    Abstract    

    Abstract available

  74. ZAMBONI S, Moschini M, Simeone C, Antonelli A, et al
    Prediction tools in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8:39-45.
    Abstract    

    Abstract available

  75. BAUMEISTER P, Zamboni S, Mattei A, Antonelli A, et al
    Histological variants in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8:34-38.
    Abstract    

    Abstract available

  76. BILSKI K, Zapala L, Skrzypczyk MA, Oszczudlowski M, et al
    Review on gender differences in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8:12-20.
    Abstract    

    Abstract available

  77. CUMBERBATCH MGK, Noon AP
    Epidemiology, aetiology and screening of bladder cancer.
    Transl Androl Urol. 2019;8:5-11.
    Abstract    

    Abstract available

  78. MOSCHINI M, Roghmann F, Xylinas E
    The present and future of non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8:1.
    Abstract    



  79. WISHAHI M, Ismail MA, Elganzoury H, Elkholy A, et al
    Genital-Sparing Cystectomy versus Standard Urethral-Sparing Cystectomy Followed with Orthotopic Neobladder in Women with Bladder Cancer: Incidence and Causes of Hypercontinence with an Ultrastructure Study of Urethral Smooth Muscles.
    Open Access Maced J Med Sci. 2019;7:978-981.
    Abstract    

    Abstract available

  80. LENFANT L, Roupret M
    [Immunotherapy and bladder cancer].
    Biol Aujourdhui. 2018;212.
    Abstract    

    Abstract available

  81. BUNCH BL, Ma Y, Attwood K, Amable L, et al
    Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk.
    Cancer Med. 2019 Apr 10. doi: 10.1002/cam4.2119.
    Abstract    

    Abstract available

  82. MORTADA WI, Abdelghany AM
    Preconcentration of Lead in Blood and Urine Samples Among Bladder Cancer Patients Using Mesoporous Strontium Titanate Nanoparticles.
    Biol Trace Elem Res. 2019 Apr 10. pii: 10.1007/s12011-019-01704.
    Abstract    

    Abstract available

  83. JIANG Y, Wei T, Li W, Zhang R, et al
    Circular RNA hsa_circ_0002024 suppresses cell proliferation, migration, and invasion in bladder cancer by sponging miR-197-3p.
    Am J Transl Res. 2019;11:1644-1652.
    Abstract    

    Abstract available

  84. BAYKAN O, Akgul M, Uren N, Yaman A, et al
    The Relationship Between Urothelial Type Bladder Cancer, Plasma 25-Hydroxyvitamin D Levels, and Vitamin D Receptor ApaI BsmI FokI, and TaqI Polymorphisms.
    Clin Lab. 2019;65.
    Abstract    

    Abstract available

  85. SUN J, Zhang H, Tao D, Xie F, et al
    CircCDYL inhibits the expression of C-MYC to suppress cell growth and migration in bladder cancer.
    Artif Cells Nanomed Biotechnol. 2019;47:1349-1356.
    Abstract    

    Abstract available

  86. CHENG XZ, Zhou HL, Tang SX, Jiang T, et al
    Intercellular transfer of P-glycoprotein mediates the formation of stable multidrug resistance in human bladder cancer BIU-87 cells.
    Biol Open. 2019 Apr 9. pii: bio.041889. doi: 10.1242/bio.041889.
    Abstract    

    Abstract available

  87. ERMAN A, Veranic P
    The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections.
    Polymers (Basel). 2018;10.
    Abstract    

    Abstract available

  88. SHIVAPPA N, Hebert JR, Mirsafa F, Rashidkhani B, et al
    Increased Inflammatory Potential of Diet Is Associated with Increased Risk of Bladder Cancer in an Iranian Case-Control Study.
    Nutr Cancer. 2019 Apr 9:1-8. doi: 10.1080/01635581.2019.1597902.
    Abstract    

    Abstract available

  89. LIU XK, Chen D, Li X
    MiR-335 suppresses cell proliferation and migration by upregulating CRKL in bladder cancer.
    Eur Rev Med Pharmacol Sci. 2019;23:2399-2408.
    Abstract    

    Abstract available

  90. TYAGI S, Nelivigi G, Bhagat S
    Management of Bladder Cancer in the Second Trimester of Pregnancy.
    J Obstet Gynaecol India. 2019;69.
    Abstract    



  91. MIYAKE M, Owari T, Tomizawa M, Matsui M, et al
    Long-term Changes in Renal Function, Blood Electrolyte Levels, and Nutritional Indices after Radical Cystectomy and Ileal Conduit in Patients with Bladder Cancer.
    Urol J. 2019 Apr 7. pii: 4531/1360. doi: 10.22037/uj.v0i0.4531.
    Abstract    

    Abstract available

  92. JIANG F, Qi W, Wang Y, Wang W, et al
    lncRNA PEG10 promotes cell survival, invasion and migration by sponging miR-134 in human bladder cancer.
    Biomed Pharmacother. 2019;114:108814.
    Abstract    

    Abstract available

  93. YANG Z, Liu A, Xiong Q, Xue Y, et al
    Prognostic value of differentially methylated gene profiles in bladder cancer.
    J Cell Physiol. 2019 Apr 5. doi: 10.1002/jcp.28515.
    Abstract    

    Abstract available

  94. PEARCE S, Daneshmand S
    Correction to: Enhanced Endoscopy in Bladder Cancer.
    Curr Urol Rep. 2019;20:25.
    Abstract    

    Abstract available

  95. DI MARTINO E, Alder O, Hurst CD, Knowles MA, et al
    ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
    Sci Rep. 2019;9:5740.
    Abstract    

    Abstract available

  96. WANG J, Li J, Yan G, Gao M, et al
    Preparation of a thickness-controlled Mg-MOFs-based magnetic graphene composite as a novel hydrophilic matrix for the effective identification of the glycopeptide in the human urine.
    Nanoscale. 2019;11:3701-3709.
    Abstract    

    Abstract available

  97. OKAMOTO M, Soeda T, Asamura A, Tanaka K, et al
    Functional comparison of the human epidermal growth factor receptor and telomerase reverse transcriptase promoters in canine tumor cells.
    J Vet Med Sci. 2019;81:397-400.
    Abstract    

    Abstract available

  98. WANG G, Zhou C, Conklin C, Hayes MM, et al
    Metastatic breast carcinoma to the urinary bladder-a report of 11 cases including a tumor to tumor metastasis.
    Virchows Arch. 2019;474:333-339.
    Abstract    

    Abstract available

  99. FERREIRA R, Neuparth MJ, Nogueira-Ferreira R, Magalhaes S, et al
    Exercise Training Impacts Cardiac Mitochondrial Proteome Remodeling in Murine Urothelial Carcinoma.
    Int J Mol Sci. 2018;20.
    Abstract    

    Abstract available

  100. TANAKA Y, Okamura T, Chaya R, Nagai T, et al
    Outcomes and Complications of Simultaneous Laparoscopic Cystectomy and Laparoscopic Nephroureterectomy with Umbilical Reduced Port Surgery
    Asian Pac J Cancer Prev. 2018;19:3495-3500.
    Abstract    

    Abstract available

  101. MATHES J, Todenhofer T
    Managing Toxicity of Intravesical Therapy.
    Eur Urol Focus. 2018;4:464-467.
    Abstract    

    Abstract available

  102. MOSCHINI M, Zamboni S, Mattei A, Amparore D, et al
    Bacillus Calmette-Guerin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know.
    Minerva Urol Nefrol. 2019;71:17-30.
    Abstract    

    Abstract available

  103. RENTSCH CA, Derre L, Dugas SG, Wetterauer C, et al
    Building on a Solid Foundation: Enhancing Bacillus Calmette-Guerin Therapy.
    Eur Urol Focus. 2018;4:485-493.
    Abstract    

    Abstract available

  104. ERMAN A, Kapun G, Novak S, Pavlin M, et al
    How cancer cells attach to urinary bladder epithelium in vivo: study of the early stages of tumorigenesis in an orthotopic mouse bladder tumor model.
    Histochem Cell Biol. 2019;151:263-273.
    Abstract    

    Abstract available

  105. KIM TN, Chung MK, Nam JK, Lee JZ, et al
    Effectiveness of hyaluronic acid/carboxymethylcellulose in preventing adhesive bowel obstruction after laparoscopic radical cystectomy.
    Asian J Surg. 2019;42:394-400.
    Abstract    

    Abstract available

  106. O'BRIEN T
    The Case for Photodynamic Diagnosis-assisted Resection Without Intravesical Single-shot Chemotherapy.
    Eur Urol Focus. 2018;4:470-471.
    Abstract    

    Abstract available

  107. GOEL R, Westblade LF, Kessler DA, Sfeir M, et al
    Death from Transfusion-Transmitted Anaplasmosis, New York, USA, 2017.
    Emerg Infect Dis. 2018;24:1548-1550.
    Abstract    

    Abstract available

  108. BANDARI J, Maganty A, MacLeod LC, Davies BJ, et al
    Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guerin.
    Eur Urol Focus. 2018;4:481-484.
    Abstract    

    Abstract available

  109. BURGER M
    Hexvix plus Chemo.
    Eur Urol Focus. 2018;4:468-469.
    Abstract    

    Abstract available

  110. CIMADAMORE A, Gasparrini S, Santoni M, Cheng L, et al
    Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer.
    Expert Rev Mol Diagn. 2018;18:645-655.
    Abstract    

    Abstract available

  111. ST BLANC A, Crossland NA, DiGeronimo PM, Cianciolo RE, et al
    Pathology in Practice.
    J Am Vet Med Assoc. 2018;253:53-56.
    Abstract    



  112. ISHARWAL S, Huang H, Nanjangud G, Audenet F, et al
    Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
    Hum Pathol. 2018;77:63-69.
    Abstract    

    Abstract available

  113. ZHANG Q, Mao Z, Sun J
    NF-kappaB inhibitor, BAY11-7082, suppresses M2 tumor-associated macrophage induced EMT potential via miR-30a/NF-kappaB/Snail signaling in bladder cancer cells.
    Gene. 2019 Apr 16. pii: S0378-1119(19)30392-0. doi: 10.1016/j.gene.2019.
    Abstract    

    Abstract available

  114. ZHUO D, Wu Y, Luo J, Deng L, et al
    CSTP1 inhibits IL-6 expression through targeting Akt/FoxO3a signaling pathway in bladder cancer cells.
    Exp Cell Res. 2019 Apr 16. pii: S0014-4827(19)30193.
    Abstract    

    Abstract available

  115. LI Z, Liu Z, Yao K, Qin Z, et al
    An improved ileal conduit surgery for bladder cancer with fewer complications.
    Cancer Commun (Lond). 2019;39:19.
    Abstract    

    Abstract available

  116. MAO W, Huang X, Wang L, Zhang Z, et al
    Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression.
    J Exp Clin Cancer Res. 2019;38:169.
    Abstract    

    Abstract available

  117. NGUYEN MH, Giordani MM, Thompson GR 3rd
    The double-edged sword - prosthetic joint infection following BCG treatment for bladder cancer: a case report.
    BMC Infect Dis. 2019;19:331.
    Abstract    

    Abstract available

  118. WANG Q, Zhang T, Wu J, Wen J, et al
    Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China.
    BMC Urol. 2019;19:24.
    Abstract    

    Abstract available

  119. SZARVAS T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, et al
    High soluble CGA levels are associated with poor survival in bladder cancer.
    Endocr Connect. 2019 Apr 1. pii: EC-19-0068.R1. doi: 10.1530/EC-19-0068.
    Abstract    

    Abstract available

  120. ZACHOS I, Zachou K, Dalekos GN, Tzortzis V, et al
    Management of Patients with Liver Cirrhosis and Invasive Bladder Cancer: A Case-series.
    J Transl Int Med. 2019;7:29-33.
    Abstract    

    Abstract available

  121. FERRO M, Di Lorenzo G, Vartolomei MD, Bruzzese D, et al
    Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guerin after transurethral resection of the bladder tumor.
    World J Urol. 2019 Apr 16. pii: 10.1007/s00345-019-02754.
    Abstract    

    Abstract available

  122. XIANG M, Yuan W, Zhang W, Huang J, et al
    Expression of miR-490-5p, miR-148a-3p and miR-608 in bladder cancer and their effects on the biological characteristics of bladder cancer cells.
    Oncol Lett. 2019;17:4437-4442.
    Abstract    

    Abstract available

  123. WU X, Chen B, Shi H, Zhou J, et al
    miR-758-3p suppresses human bladder cancer cell proliferation, migration and invasion by targeting NOTCH2.
    Exp Ther Med. 2019;17:4273-4278.
    Abstract    

    Abstract available

  124. HSIAO CH, Yao CJ, Lai GM, Lee LM, et al
    Honokiol induces apoptotic cell death by oxidative burst and mitochondrial hyperpolarization of bladder cancer cells.
    Exp Ther Med. 2019;17:4213-4222.
    Abstract    

    Abstract available

  125. PFANNSTIEL C, Strissel PL, Chiappinelli KB, Sikic D, et al
    The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes.
    Cancer Immunol Res. 2019 Apr 15. pii: 2326-6066.CIR-18-0758.
    Abstract    

    Abstract available

  126. CHEN YT, Huang HC, Hsieh YJ, Fu SH, et al
    Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers.
    J Food Drug Anal. 2019;27:460-474.
    Abstract    

    Abstract available

  127. HUANG Y, Cen J, Liu Z, Wei J, et al
    A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens for Bladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinomas: A Retrospective 2-center Study.
    Technol Cancer Res Treat. 2019;18:1533033819844483.
    Abstract    

    Abstract available

  128. LI M, Wang Y, Liu Y, Zhang X, et al
    Low Expression of hsa_circ_0018069 in Human Bladder Cancer and Its Clinical Significance.
    Biomed Res Int. 2019;2019:9681863.
    Abstract    

    Abstract available

  129. DING B, Yan L, Zhang Y, Wang Z, et al
    Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer.
    FEBS Open Bio. 2019;9:693-706.
    Abstract    

    Abstract available

  130. YANG L, Li YL, Li XQ, Zhang Z, et al
    High Apelin Level Indicates a Poor Prognostic Factor in Muscle-Invasive Bladder Cancer.
    Dis Markers. 2019;2019:4586405.
    Abstract    

    Abstract available

  131. LIU Y, Lu J, Huang Y, Ma L, et al
    Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guerin for Bladder Cancer.
    J Oncol. 2019;2019:6230409.
    Abstract    

    Abstract available

  132. LI Y, Shi B, Dong F, Zhu X, et al
    Long Non-coding RNA DLEU1 Promotes Cell Proliferation, Invasion, and Confers Cisplatin Resistance in Bladder Cancer by Regulating the miR-99b/HS3ST3B1 Axis.
    Front Genet. 2019;10:280.
    Abstract    

    Abstract available

  133. YANG FY, Wang WK, Liu S, Song LM, et al
    [Clinical experiences of laparoscopic radical cystectomy and urinary diversion in the elderly patients with bladder cancer].
    Zhonghua Yi Xue Za Zhi. 2019;99:1101-1105.
    Abstract    

    Abstract available

  134. HOUEDE N, Milano G
    [Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine].
    Bull Cancer. 2019 Apr 10. pii: S0007-4551(19)30146.
    Abstract    

    Abstract available

  135. XU X, Wang H, Du P, Zhang F, et al
    A predictive nomogram for individualized recurrence stratification of bladder cancer using multiparametric MRI and clinical risk factors.
    J Magn Reson Imaging. 2019 Apr 13. doi: 10.1002/jmri.26749.
    Abstract    

    Abstract available

  136. ROUVINOV K, Plimack ER, Zibelman M, Ghatalia P, et al
    Update on perioperative systemic therapy for urothelial carcinoma.
    Clin Adv Hematol Oncol. 2019;17:176-183.
    Abstract    

    Abstract available

  137. HANNA KS
    Updates and novel treatments in urothelial carcinoma.
    J Oncol Pharm Pract. 2019;25:648-656.
    Abstract    

    Abstract available

  138. PENG H, Li H
    The encouraging role of long noncoding RNA small nuclear RNA host gene 16 in epithelial-mesenchymal transition of bladder cancer via directly acting on miR-17-5p/metalloproteinases 3 axis.
    Mol Carcinog. 2019 Apr 26. doi: 10.1002/mc.23028.
    Abstract    

    Abstract available

  139. BUSS JH, Begnini KR, Bruinsmann FA, Ceolin T, et al
    Lapatinib-Loaded Nanocapsules Enhances Antitumoral Effect in Human Bladder Cancer Cell.
    Front Oncol. 2019;9:203.
    Abstract    

    Abstract available

  140. XU Z, Wang C, Xiang X, Li J, et al
    Characterization of mRNA Expression and Endogenous RNA Profiles in Bladder Cancer Based on The Cancer Genome Atlas (TCGA) Database.
    Med Sci Monit. 2019;25:3041-3060.
    Abstract    

    Abstract available

  141. JERLSTROM T, Chen R, Liedberg F, Andren O, et al
    No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study.
    World J Urol. 2019 Apr 24. pii: 10.1007/s00345-019-02770.
    Abstract    

    Abstract available

  142. LOTAN Y, Bivalacqua TJ, Downs T, Huang W, et al
    Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
    Nat Rev Urol. 2019 Apr 24. pii: 10.1038/s41585-019-0184.
    Abstract    

    Abstract available

  143. GANDAGLIA G, Larcher A, Gallina A, Fossati N, et al
    Requiem for Open Radical Cystectomy in Bladder Cancer Patients.
    Eur Urol Oncol. 2019;2:196-197.
    Abstract    

    Abstract available

  144. WILLIAMS SB, Hudgins HK, Ray-Zack MD, Chamie K, et al
    Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer.
    Eur Urol Oncol. 2019;2:119-125.
    Abstract    

    Abstract available

  145. RAI BP, Bondad J, Vasdev N, Adshead J, et al
    Robotic versus open radical cystectomy for bladder cancer in adults.
    Cochrane Database Syst Rev. 2019;4:CD011903.
    Abstract    

    Abstract available

  146. WANG H, Hu D, Yao H, Chen M, et al
    Radiomics analysis of multiparametric MRI for the preoperative evaluation of pathological grade in bladder cancer tumors.
    Eur Radiol. 2019 Apr 23. pii: 10.1007/s00330-019-06222.
    Abstract    

    Abstract available

  147. ZHU J, Tian Z, Li Y, Hua X, et al
    ATG7 Promotes Bladder Cancer Invasion via Autophagy-Mediated Increased ARHGDIB mRNA Stability.
    Adv Sci (Weinh). 2019;6:1801927.
    Abstract    

    Abstract available

  148. MARTINEZ-BOSCH N, Rodriguez-Vida A, Juanpere N, Lloreta J, et al
    Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities.
    Nat Rev Urol. 2019 Apr 23. pii: 10.1038/s41585-019-0183.
    Abstract    

    Abstract available

  149. AYOUB M, Shinde-Jadhav S, Mansure JJ, Alvarez F, et al
    The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance.
    Sci Rep. 2019;9:6348.
    Abstract    

    Abstract available

  150. MARGOLIS DJA, Hu JC
    Vying for Standardization of Bladder Cancer MRI Interpretation and Reporting: VI-RADS.
    Radiology. 2019 Apr 23:190648. doi: 10.1148/radiol.2019190648.
    Abstract    



  151. WANG H, Luo C, Zhang F, Guan J, et al
    Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion.
    Radiology. 2019 Apr 23:182506. doi: 10.1148/radiol.2019182506.
    Abstract    

    Abstract available

  152. RAVEN PA, Lysakowski S, Tan Z, D'Costa NM, et al
    Inhibition of GLI2 with antisense-oligonucleotides: A potential therapy for the treatment of bladder cancer.
    J Cell Physiol. 2019 Apr 22. doi: 10.1002/jcp.28669.
    Abstract    

    Abstract available

  153. FLORES-MARTIN JF, Perea F, Exposito-Ruiz M, Carretero FJ, et al
    A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Ann Surg Oncol. 2019 Apr 22. pii: 10.1245/s10434-019-07371.
    Abstract    

    Abstract available

  154. KRAJEWSKI W, Poletajew S
    The TaHG bladder cancer - the devil is as black as he is painted.
    Cent European J Urol. 2019;72:76-77.
    Abstract    



  155. MORTAZAVI N, Asadikaram G, Ebadzadeh MR, Kamalati A, et al
    Organochlorine and organophosphorus pesticides and bladder cancer: A case-control study.
    J Cell Biochem. 2019 Apr 22. doi: 10.1002/jcb.28746.
    Abstract    

    Abstract available

  156. DENG S, Ren ZJ, Jin T, Yang B, et al
    Contribution of prostate stem cell antigen variation rs2294008 to the risk of bladder cancer.
    Medicine (Baltimore). 2019;98:e15179.
    Abstract    

    Abstract available

  157. UMEZAWA Y, Shirotake S, Kaneko G, Nishimoto K, et al
    Meningeal carcinomatosis from bladder cancer: A case report and review of the literature.
    Mol Clin Oncol. 2019;10:506-510.
    Abstract    

    Abstract available

  158. OURFALI S, Ohannessian R, Fassi-Fehri H, Pages A, et al
    Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guerin Connaught Strain for Bladder Cancer Patients.
    Eur Urol Focus. 2019 Apr 17. pii: S2405-4569(19)30109.
    Abstract    

    Abstract available

  159. LI T, Zou L, Zhang J, Li G, et al
    Non-invasive diagnosis of bladder cancer by detecting telomerase activity in human urine using hybridization chain reaction and dynamic light scattering.
    Anal Chim Acta. 2019;1065:90-97.
    Abstract    

    Abstract available

  160. HOU G, Jiang Y, Jian S, Niu Y, et al
    Hemolymphangioma involving bones and bladder detected on 68Ga-NEB PET/CT: A rare case report.
    Medicine (Baltimore). 2019;98:e15213.
    Abstract    

    Abstract available

  161. LIN Z, Hu WM, Li YH, Jiang LJ, et al
    [Surgical treatment for inflammatory myofibroblastic tumor in genito-urinary system: a study of 15 cases].
    Zhonghua Yi Xue Za Zhi. 2019;99:947-949.
    Abstract    

    Abstract available

  162. LEE HY, Chen YJ, Li CC, Li WM, et al
    Deduction of Novel Genes Potentially Involved in Upper Tract Urothelial Carcinoma Using Next-Generation Sequencing and Bioinformatics Approaches.
    Int J Med Sci. 2019;16:93-105.
    Abstract    

    Abstract available

  163. KUMAR P, Nayyar R, Seth A, Gupta D, et al
    Management of cavernous abdominal wall defects post radical cystectomy in adult exstrophy complex.
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  164. HANADA E, Kageyama S, Murai R, Kubota S, et al
    Pro-GA, a Novel Inhibitor of gamma-Glutamylcyclotransferase, Suppresses Human Bladder Cancer Cell Growth.
    Anticancer Res. 2019;39:1893-1898.
    Abstract    

    Abstract available

  165. HUANG AC, Cheng YD, Huang LH, Hsiao YT, et al
    Casticin Induces DNA Damage and Impairs DNA Repair in Human Bladder Cancer TSGH-8301 Cells.
    Anticancer Res. 2019;39:1839-1847.
    Abstract    

    Abstract available

  166. GROSS T, Furrer M, Schorno P, Wuethrich PY, et al
    Reproductive organ-sparing cystectomy significantly improves continence in women after orthotopic bladder substitution without affecting oncological outcome.
    BJU Int. 2018;122:227-235.
    Abstract    

    Abstract available

  167. MOSSANEN M, Kibel AS
    The bladder cancer conundrum: how do we treat the right tumour with the right treatment, at the right time?
    BJU Int. 2019;123:748-749.
    Abstract    



  168. BATISTA DA COSTA J, Gibb EA, Bivalacqua TJ, Liu Y, et al
    Molecular characterization of neuroendocrine-like bladder cancer.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3558.
    Abstract    

    Abstract available

  169. CHENG THT, Jiang P, Teoh JYC, Heung MMS, et al
    Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling.
    Clin Chem. 2019 Apr 15. pii: clinchem.2018.301341.
    Abstract    

    Abstract available

  170. DASON S, Goh AC
    Contemporary techniques and outcomes of robotic cystectomy and intracorporeal urinary diversions.
    Curr Opin Urol. 2018;28:115-122.
    Abstract    

    Abstract available

  171. UENO Y, Takeuchi M, Tamada T, Sofue K, et al
    Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study.
    Eur Urol. 2019 Mar 25. pii: S0302-2838(19)30198.
    Abstract    

    Abstract available

  172. MOUW KW, Miyamoto DT, Efstathiou JA
    Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.040: Towards Biomarker-Informed M
    Eur Urol. 2019 Mar 22. pii: S0302-2838(19)30195.
    Abstract    



  173. SHI MJ, Meng XY, Lamy P, Banday AR, et al
    APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
    Eur Urol. 2019 Apr 8. pii: S0302-2838(19)30261.
    Abstract    

    Abstract available

  174. GUST KM, Shariat SF
    Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study.
    Eur Urol. 2019;75:695-696.
    Abstract    



  175. LERNER SP, Svatek RS
    What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy?
    Eur Urol. 2019;75:612-614.
    Abstract    



  176. SORIA F, Gontero P
    Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30275.
    Abstract    



  177. SAITA A, Lughezzani G, Buffi NM, Hurle R, et al
    Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging.
    Eur Urol. 2019 Apr 10. pii: S0302-2838(19)30277.
    Abstract    

    Abstract available

  178. SUN M, Zhao W, Chen Z, Li M, et al
    Circular RNA CEP128 Promotes Bladder Cancer Progression by Regulating Mir-145-5p/Myd88 Via Mapk Signaling Pathway.
    Int J Cancer. 2019 Apr 2. doi: 10.1002/ijc.32311.
    Abstract    

    Abstract available

  179. WU Q, Fu C, Li M, Li J, et al
    CINP is a novel cofactor of KLF5 required for its role in the promotion of cell proliferation, survival and tumor growth.
    Int J Cancer. 2019;144:582-594.
    Abstract    

    Abstract available

  180. SUGITA S, Yoshino H, Yonemori M, Miyamoto K, et al
    Tumorsuppressive microRNA223 targets WDR62 directly in bladder cancer.
    Int J Oncol. 2019 Mar 22. doi: 10.3892/ijo.2019.4762.
    Abstract    

    Abstract available

  181. LIN JF, Tsai TF, Lin YC, Chen HE, et al
    Benzyl isothiocyanate suppresses IGF1R, FGFR3 and mTOR expression by upregulation of miR-99a-5p in human bladder cancer cells.
    Int J Oncol. 2019 Mar 26. doi: 10.3892/ijo.2019.4763.
    Abstract    

    Abstract available

  182. NAKAYAMA M, Ito Y, Hatano K, Nakai Y, et al
    Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan.
    Int J Urol. 2019 Mar 27. doi: 10.1111/iju.13955.
    Abstract    

    Abstract available

  183. MAO W, Ma B, Huang X, Gu S, et al
    Which treatment is best for patients with AJCC stage IV bladder cancer?
    Int Urol Nephrol. 2019 Apr 4. pii: 10.1007/s11255-019-02105.
    Abstract    

    Abstract available

  184. MILOJEVIC B, Dzamic Z, Bojanic N, Durutovic O, et al
    Urothelial carcinoma of the upper urinary tract: preoperative pyuria is not correlated with bladder cancer recurrence and survival.
    Int Urol Nephrol. 2019 Apr 1. pii: 10.1007/s11255-019-02133.
    Abstract    

    Abstract available

  185. CHANG SS
    Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy.
    J Urol. 2019 Mar 29:10109701JU0000557728168538.
    Abstract    



  186. CHANG SS
    Re: Contemporary Treatment Patterns and Outcomes of Sarcomatoid Bladder Cancer.
    J Urol. 2019 Mar 29:101097JU0000000000000252. doi: 10.1097/JU.0000000000000252.
    Abstract    



  187. CHANG SS
    Re: Mutational Patterns in Chemotherapy Resistant Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Mar 29:10109701JU000055772739723.
    Abstract    



  188. PARKER DC, Abboud MA, Patel SG
    Is Routine Removal of the Ovaries Advisable during Radical Cystectomy?
    J Urol. 2019;201:455-456.
    Abstract    



  189. XUE W, Yang L, Wei Q
    Re: Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: R. S. Liao, M. Gupta, Z. R. Schwen, H. D. Patel, M. Kates, M. H. Johnson, N. M. Hahn, D. McConkey, T. J.
    J Urol. 2018;200:1378-1379.
    Abstract    



  190. WHITSON JM
    Editorial Comment.
    J Urol. 2018;200:539-540.
    Abstract    



  191. HAMILTON-REEVES JM, Stanley A, Bechtel MD, Yankee TM, et al
    Perioperative Immunonutrition Modulates Inflammatory Response after Radical Cystectomy: Results of a Pilot Randomized Controlled Clinical Trial.
    J Urol. 2018;200:292-301.
    Abstract    

    Abstract available

  192. ABUFARAJ M, Tabung FK, Shariat SF, Moschini M, et al
    Association between inflammatory potential of diet and bladder cancer risk:Results from three US prospective cohort studies.
    J Urol. 2019 Apr 22:101097JU0000000000000279. doi: 10.1097/JU.0000000000000279.
    Abstract    

    Abstract available

  193. WU M, Sheng L, Cheng M, Zhang H, et al
    Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells.
    Oncogene. 2019 Mar 27. pii: 10.1038/s41388-019-0799.
    Abstract    

    Abstract available

  194. ALBISINNI S, Moussa I, Aoun F, Quackels T, et al
    The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer.
    Prog Urol. 2019 Apr 3. pii: S1166-7087(19)30043.
    Abstract    

    Abstract available

  195. MOUDOUNI SM, Latabi A, Mouaad A, Lakmichi MA, et al
    [Evaluation of the learning curve of laparoscopic radical cystectomy for cancer: Morbidity and oncological results].
    Prog Urol. 2019;29:50-62.
    Abstract    

    Abstract available

  196. ZIESCHANG H, Koch R, Wirth MP, Froehner M, et al
    Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis.
    Urol Int. 2019;102:96-101.
    Abstract    

    Abstract available

  197. TAE BS, Ku JH, Kwak C, Kim HH, et al
    Comparison of Renal Function after Radical Surgery for Upper Tract Urothelial Carcinoma versus Renal Cell Carcinoma: Propensity Score Matching.
    Urol Int. 2018;101:400-408.
    Abstract    

    Abstract available

  198. LI A, Zhang P, Zhang M, Yang T, et al
    Transurethral Enucleation of Bladder Leiomyoma: A Series of Six Cases and Review of the Literature.
    Urol Int. 2019;102:102-108.
    Abstract    

    Abstract available

  199. BO S, Donghao S, Guangqi K, Ye T, et al
    CC Chemokine Ligand 18 Promotes Cell Proliferation and Metastasis of Urothelial Carcinoma via Activating PI3K/mTOR Signaling in Patient with Renal Transplantation.
    Urol Int. 2018;101:450-458.
    Abstract    

    Abstract available

  200. LORENZO SORIANO L, Ordaz Jurado G, Pontones Moreno JL, Villarroya Castillo S, et al
    TUMOR BUDDING: PROGNOSTIC VALUE IN MUSCLE-INVASIVE BLADDER CANCER.
    Urology. 2019 Apr 12. pii: S0090-4295(19)30344.
    Abstract    

    Abstract available

  201. MAGANTY A, Turner RM 2nd, Yabes JG, Davies BJ, et al
    Downstream Studies Following the Use of Bone Scan in the Staging of Muscle-invasive Bladder Cancer.
    Urology. 2019 Apr 18. pii: S0090-4295(19)30353.
    Abstract    

    Abstract available

  202. YASUI M, Kawahara T, Izumi K, Yao M, et al
    Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.
    BMC Cancer. 2019;19:331.
    Abstract    

    Abstract available

  203. AL-HUSSEINI MJ, Kunbaz A, Saad AM, Santos JV, et al
    Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis.
    BMC Cancer. 2019;19:46.
    Abstract    

    Abstract available

  204. YU A, Mansure JJ, Solanki S, Siemens DR, et al
    Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy.
    PLoS One. 2018;13:e0205746.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;